Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Pension (2023 - 2025)

Historic Pension for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $4.7 million.

  • Monte Rosa Therapeutics' Pension rose 6790.65% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 6790.65%. This contributed to the annual value of $3.7 million for FY2024, which is 3645.41% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Pension stood at $4.7 million for Q3 2025, which was up 6790.65% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Pension ranged from a high of $4.7 million in Q3 2025 and a low of $1.5 million during Q3 2023
  • Its 3-year average for Pension is $2.9 million, with a median of $2.7 million in 2023.
  • Data for Monte Rosa Therapeutics' Pension shows a peak YoY increase of 9428.77% (in 2024) and a maximum YoY decrease of 3645.41% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Pension (Quarter) stood at $2.7 million in 2023, then soared by 36.45% to $3.7 million in 2024, then grew by 28.04% to $4.7 million in 2025.
  • Its Pension was $4.7 million in Q3 2025, compared to $4.6 million in Q2 2025 and $4.0 million in Q1 2025.